Source: Virtual Congress 2021 – Biology of lung cancer: preclinical and translational research



Rating:

Share or cite this content

Citations should be made in the following way:
J. Moes-Sosnowska (Warsaw, Poland), A. Rozy (Warsaw, Poland), M. Skupinska (Kielpin/Lomianki, Poland), U. Lechowicz (Warsaw , Poland), E. Szczepulska-Wojcik (Warsaw , Poland), R. Langfort (Warsaw , Poland), P. Rudzinski (Warsaw , Poland), T. Orlowski (Warsaw , Poland), D. Popiel (Kielpin/Lomianki, Poland), M. Wieczorek (Kielpin/Lomianki, Poland), A. Stanczak (Kielpin/Lomianki, Poland), J. Chorostowska-Wynimko (Warsaw, Poland). FGFR1 gene aberrations and FGFR1 protein expression in squamous non-small cell lung cancer (Sq-NSCLC).. 1126

Member's Comments

No comment yet.

Related content which might interest you: HER-2/neu oncoprotein expression in nonsmall cell lung cancer Source: Eur Respir J 2002; 20: Suppl. 38, 230s Year: 2002 An analysis of EGFR expression and tumour imaging in non-small cell carcinomas of lung Source: Annual Congress 2011 - Imaging, functional evaluation and staging for lung cancer patients Year: 2011 Survivin expression in non-small cell lung cancer Source: Annual Congress 2010 - Recent developments of molecular pathology and functional genomics in non-neoplastic and neoplastic lung diseases Year: 2010 Expression of Fhit protein in non-small cell lung cancer (NSCLC) and its correlation with Ki-67, a proliferative marker Source: Eur Respir J 2002; 20: Suppl. 38, 230s Year: 2002 Mutant P53 expression in squamous cell lung cancer Source: Eur Respir J 2002; 20: Suppl. 38, 72s Year: 2002 Characterization of patients with non-small cell lung cancer (NSCLC) relative to its EGFR mutational status Source: Annual Congress 2011 - Epidemiology of lung cancer and screening Year: 2011 Investigation of survivin gene polymorphism in non-small cell lung cancer patients (NSCLC) Source: Annual Congress 2012 - New biomarkers for lung cancer Year: 2012 p53 and mdm2 expression in nonsmall cell lung cancer (NSCLC): the lack of prognostic relevance Source: Eur Respir J 2001; 18: Suppl. 33, 230s Year: 2001 Choice of endogenous control for gene expression in nonsmall cell lung cancer Source: Eur Respir J 2005; 26: 1002-1008 Year: 2005 Clinical relevance of p53 and K-ras mutations in nonsmall cell lung cancer (NSCLC) Source: Eur Respir J 2001; 18: Suppl. 33, 230s Year: 2001 How to treat brain metastasis in patients with non-small cell lung carcinoma (NSCLC) and EGFR mutations Source: International Congress 2015 – How to treat brain metastases Year: 2015 Prognostic value of p21 protein expression in non-small cell lung cancer Source: Eur Respir J 2004; 24: Suppl. 48, 674s Year: 2004 The prognostic value of altered pRb and p53 protein expression in non-small cell lung cancer Source: Eur Respir J 2003; 22: Suppl. 45, 363s Year: 2003 Expression and significance of VE-cadherin and E-cadherin in non-small cell lung cancer Source: Annual Congress 2011 - Progress in pathology of lung cancer Year: 2011 Expression of ERCC1 in normal and tumor tissues in non-small cell lung cancer Source: Annual Congress 2007 - Biology of thoracic malignancies Year: 2007 Expression of Her-2/neu and Bcl-2 in patients with non-small cell lung cancer Source: International Congress 2017 – Gene signatures in bronchial diseases Year: 2017 Expression of RASGRF2 in non-small cell lung cancer and its effect of transfection on biological behavior of human NSCLC lines H1299 Source: Annual Congress 2012 - New aspects of lung cancer biology Year: 2012 Clinical features associated with epidermal growth factor receptor and K-RAS gene mutations in non-small cell lung cancer Source: Eur Respir J 2006; 28: Suppl. 50, 811s Year: 2006 Her/2 neu and p53 expression in patients with non-small cell lung cancer predict shortened survival Source: Annual Congress 2010 - Biomarkers for lung cancer Year: 2010 Aberrant methylation of p16 tumour suppresor gene and DAP kinase in nonsmall cell lung carcinomas Source: Eur Respir J 2001; 18: Suppl. 33, 233s Year: 2001